For a growing number of patients with diabetes, concentrated insulins may be the ideal agents in order to best address challenges of insulin resistance while improving health outcomes. However, the unique properties of these agents mean that each form of concentrated insulin serves a specific function in the overall management of diabetes. It is critical that clinicians are comfortable distinguishing concentrated insulins and selecting ideal patients for treatment as an intimate knowledge of these agents will allow clinicians to optimize treatment and reduce risks. In this interactive case-based roundtable discussion, expert faculty will guide learners through overcoming barriers associated with insulin use, distinguishing among approved concentrated insulin products, identifying patients who would benefit from concentrated insulin therapy, and employing best practices in management in order to minimize risks such as hypoglycemia.
The landscape of diabetes treatment has shifted from a “one-size-fits-all” paradigm to one involving individualized care accounting for patient factors, preferences, and comorbidities. Participate in this 90-minute expert panel discussion to learn about the safety and efficacy of newer non-insulin therapies for type 2 diabetes, such as SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and their combinations. Faculty experts will answer crucial participant questions, explain considerations for selecting therapies based on guideline recommendations, and distill the latest clinical data for non-insulin T2DM management into concepts relevant to primary care.
In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).
Insulin therapy is more complicated than ever. This important session will teach you how to leverage the many choices of basal, short- and rapid-acting, and premixed insulins, and how to combine them with noninsulin therapies in order to optimize glycemic control, improve adherence, and reduce the risk of hypoglycemia. We will also review new insulin formulations in development and discuss overcoming barriers to injectable therapies.
This case examines the management of a patient experiencing episodes of nocturnal hypoglycemia on premixed and prandial insulin. Areas of concentration include switching to ultra-long-acting basal insulin (including dose conversions), hypoglycemia self-management, depression and anxiety in patients with diabetes, and lipodystrophy.
In this case presentation, Dr. Mathioudakis shares strategies for treatment intensification while minimizing the risk of hypoglycemia and highlights the differences between conventional and newer basal insulin products. He also describes how to appropriately initiate and dose newer basal insulin products in patients with type 2 diabetes.
This case discusses treatment intensification with the combination of a GLP-1 RA and basal insulin in a patient with uncontrolled T2DM. Treatment decisions will include individualized HbA1c guideline recommendations, patient preference, cardiovascular risk, and other comorbidities such as visual impairment.
In this Expert Perspective, Dr. Vanita Aroda answers important questions about the benefits and use of ultra-long-acting insulins as well as ways to overcome the therapeutic inertia associated with initiating and intensifying insulin therapy.
This patient case highlights the role of the newer, long-acting basal insulins in managing T2DM. It will include a practical discussion on initiating long-acting insulin and mitigating the side effects of hypoglycemia and lipodystrophy.
This case follows treatment intensification in a patient with T2DM that remains uncontrolled on oral therapy. Participants will consider ways to overcome barriers to injectable therapy, advance to combination injectable therapy, and determine the best fixed-ratio GLP-1 RA/basal insulin formulation based on the patient’s blood glucose readings.